Treating oral disease is often reactive, detecting disease when symptoms are already present and irreversible. Teeth are surgically drilled to fill existing decay and gums are grafted to fill recession. Bristle is an early-stage venture-backed startup company aiming to prevent oral disease and improve oral health outcomes through our unique platform that analyzes the oral microbiome.
Our mission is to enable preventative oral health treatments, develop novel therapeutics to improve oral health and democratize access to oral health care. We believe an ounce of prevention is worth a pound of cure.
Oral diseases, such as cavities and gum disease, stem from an overabundance of bacterial pathogens that are part of a community of bacteria, fungi, and viruses also known as the oral microbiome.
We have developed a diagnostic platform to screen for oral diseases by leveraging the oral microbiome and next-generation sequencing. Our product is an at-home saliva test that detects the earliest signs of cavities and gum disease. By sequencing the oral microbiome, we can provide personalized treatment plans tailored to an individual's oral microbiome to prevent oral disease from progressing irreversibly.
Through the comprehensive unbiased profiling of the oral microbiome, we are poised to make discoveries that advance our basic understanding of science. Our platform enables the exploration of associations between the oral microbiome and health, facilitating the development of novel therapeutic drugs that target the oral microbiome to improve health outcomes.
Our team is spread across the US and Canada working together to usher in a new standard of oral health care.
Research and Development
📊 Make data driven decisions.
👩🔬 Innovation should benefit everyone.
⚖️ Balance is key.
👨👩👧👦 Everybody deserves the opportunity to improve their health.
🥇 Patients and people first.